HMGB1: A POTENTIAL THERAPEUTIC TARGET FOR NON-SMALL CELL LUNG CANCER
Open Access
- 1 January 2016
- journal article
- Published by Ommega Online Publishers in Letters in Health and Biological Sciences
- Vol. 1 (2), 1-2
- https://doi.org/10.15436/2475-6245.16.008
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancerOncotarget, 2016
- Genomic alterations in lung adenocarcinomaThe Lancet Oncology, 2015
- Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cellsIUBMB Life, 2015
- Targeting VEGF in lung cancerEmerging Therapeutic Targets, 2012
- HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cellsLeukemia, 2010
- HMGB1 release and redox regulates autophagy and apoptosis in cancer cellsOncogene, 2010
- HMGB proteins: Interactions with DNA and chromatinBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- High-mobility group box 1 and cancerBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian PerspectiveJapanese Journal of Clinical Oncology, 2008
- Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future DevelopmentThe Oncologist, 2007